Sarcopenia , as defined by reduced muscle mass alone , was found to be very prevalent in patients with lung cancer , regardless of body mass index , and where present was associated with poorer functional status and overall survival .
The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results .
There are very limited data on the correlation between degree of sarcopenia and muscle function , which has a non-linear relationship in older non-cancer population s. CONCLUSIONS Loss of muscle mass is a significant contributor to morbidity in patients with lung cancer .
OBJECTIVES There is growing awareness of the relationship between sarcopenia ( loss of muscle mass and function ) , and outcomes in cancer , making it a potential target for future therapies .
In order to inform future research and practice , we undertook a systematic review of factors associated with loss of muscle mass , and the relationship between muscle function and muscle mass in lung cancer , a common condition associated with poor outcomes .
Association of Nutrition Parameters Including Bioelectrical Impedance and Systemic Inflammatory Response With Quality of Life and Prognosis in Patients With Advanced Non-Small-Cell Lung Cancer: A Prospective Study
Early identification and treatment of nutritional deficiencies can lead to improved outcomes in the quality of life ( QoL ) and survival of patients with nonsmall cell lung cancer ( NSCLC ) . Noninvasive techniques are needed to evaluate changes in body composition as part of determining nutritional status . The aim of the study was to evaluate the association of nutritional parameters in health-related quality of life ( HRQL ) and survival in patients with advanced NSCLC . Chemotherapy-naïve patients with advanced NSCLC with good performance status Eastern Cooperative Oncology Group ( ECOG ) 0–2 were included prospect ively in the study . We evaluated inflammatory parameters such as C-reactive protein , platelet/lymphocyte index , neutrophil/lymphocyte index , serum interleukin (IL)-6 , and tumor necrosis factor-α , and nutritional variables such as body mass index ( BMI ) and serum albumin levels . Bioelectrical impedance analysis including phase angle was obtained before cisplatin-based chemotherapy was started  . HRQL was assessed by application of the European Organization for Research and Treatment of Cancer Quality of Life Question naire (QLQ)-C30 and QLQ-LC13 instruments at baseline . Overall survival ( OS ) was calculated with the Kaplan-Meier method and analyzed with log-rank and Cox proportional hazard models . One hundred nineteen patients were included .  Mean BMI was 24.8 ± 4.5 kg/m2 , average weight loss of patients was 8.4 % , and median phase angle was 5.8 ° . Malnutrition measured by subjective global assessment ( SGA ) , weight loss > 10 % , BMI > 20 was associated with lower HRQL scales . Patients with ECOG 2 , high content serum IL-6 , lower phase angle , and malnutrition parameters showed lower OS ; however , after multivariate analysis , only ECOG 2 [ Hazard ratio ( HR ) , 2.7 ; 95 % confidence interval ( 95 % CI ) , 1.5–4.7 ; P = 0.001 ] , phase angle ≤5.8 ° ( HR = 3.02 ; 95 % CI : 1.2–7.11 ; P = 0.011 ) , and SGA ( HR = 2.7 ; 95 % CI , 1.31–5.5 ; P = 0.005 ) were associated with poor survival . Patients were divided into low- , intermediate- , and high-risk groups according to regression coefficients ; OS at 1 yr was 78.4 , 53 , and 13.8 % , respectively . Malnutrition is associated with low HRQL and is an independent prognostic factor in advanced NSCLC . The results warrant prospect i ve trials to evaluate the impact of different nutritional interventions on HRQL and survival
Sarcopenia , as defined by reduced muscle mass alone , was found to be very prevalent in patients with lung cancer , regardless of body mass index , and where present was associated with poorer functional status and overall survival .
The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results .
There are very limited data on the correlation between degree of sarcopenia and muscle function , which has a non-linear relationship in older non-cancer population s. CONCLUSIONS Loss of muscle mass is a significant contributor to morbidity in patients with lung cancer .
OBJECTIVES There is growing awareness of the relationship between sarcopenia ( loss of muscle mass and function ) , and outcomes in cancer , making it a potential target for future therapies .
In order to inform future research and practice , we undertook a systematic review of factors associated with loss of muscle mass , and the relationship between muscle function and muscle mass in lung cancer , a common condition associated with poor outcomes .